



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Stephen J. Brand  
SERIAL NUMBER: 10/044,048 EXAMINER: Not Yet Assigned  
FILING DATE: January 11, 2002 ART UNIT: 1619  
FOR: Prolonged Efficacy of Islet Neogenesis Therapy Methods With a  
Gastrin/CCK Receptor Ligand and an EGF Receptor Ligand Composition in  
Subjects with Preexisting Diabetes

April 5, 2002  
Boston, Massachusetts

Commissioner for Patents  
Washington, D.C. 20231

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (2 pages) in duplicate;
2. Modified Form 1449/PTO (1 page) in duplicate;
3. Copies of cited references A1-A3, B1-B2 and C1-C4; and
4. Return Postcard.

No fee is believed to be due. However, if any fees are to be assessed, the Commissioner is hereby authorized to charge the balance due to the undersigned's account, Deposit Account No. 50-0311, Reference No. 24492-006. A duplicate copy of this transmittal letter is enclosed.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617/542-6000, Boston, Massachusetts.


Respectfully submitted,

Sonia K. Guterman, Esq. (Reg. No. 44,729)  
Attorney for Applicants

c/o MINTZ, LEVIN, COHN, FERRIS  
GLOVSKY AND POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241



RECEIVED  
APR 10 2002  
TECH CENTER 1600/2900



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT: Stephen J. Brand

SERIAL NUMBER: 10/044,048

FILING DATE: January 11, 2002

EXAMINER: Not Yet Assigned

ART UNIT: 1619

FOR: Prolonged Efficacy of Islet Neogenesis Therapy Methods With a Gastrin/CCK Receptor  
Ligand and an EGF Receptor Ligand Composition in Subjects with Preexisting Diabetes

April 5, 2002  
Boston, Massachusetts

RECEIVED  
APR 10 2002  
TECH CENTER 1600/2900

**BOX IDS**

Assistant Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicant hereby makes of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.


This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-identified case. Accordingly, no fee or certification is required as set forth in 37 C.F.R. §1.97.

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached modified Form PTO-1449. It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed Form PTO-1449 to evidence that the cited information has been fully considered by the PATENT AND TRADEMARK OFFICE during the examination of this application.

Applicant: Stephen J. Brand  
U.S.S.N.: 10/044,048

Please charge any fees that may be due, or credit any overpayment of same, to Deposit  
Account No. 50-0311 (Reference No. 24492-006).

Respectfully submitted,

A handwritten signature in cursive script, reading "Sonia K. Guterman", is written over a horizontal line.

Sonia K. Guterman, Esq. (Reg. No. 44,729)

Attorney for the Applicant

c/o MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

TRA 1653117v1



Please type a plus sign (+) in this box

+

PTO/SI 12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	10/044,048
	<b>Filing Date</b>	January 11, 2002
	<b>First Named Inventor</b>	Brand
	<b>Group Art Unit</b>	1619
	<b>Examiner Name</b>	Not Yet Assigned
	<b>Attorney Docket Number</b>	24492-006

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	4,760,023	07/26/88	Miyoshi et al.			07/03/84
	A2	5,885,956	03/23/99	Nardi et al.			12/14/92
	A3	6,288,301	09/11/01	Nardi et al.			07/30/98

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B1	WO	93/03757	Chiron Corporation	03/04/93		
	B2	WO	00/29438	Millennium Pharmaceuticals, Inc.	05/25/00		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	C1	Carpenter and Cohen (1976). <i>J. Cell. Physiol.</i> 88: 227-238.					
	C2	Carpenter and Wahl in <i>Peptide Growth Factors</i> , Chapter 4, "The Epidermal Growth Factor Family" eds. Sporn and Roberts, Springer Verlag, 1990.					
	C3	Gasslander et al. (1997). <i>Eur. Surg. Res.</i> 29: 142-149.					
	C4	Karnes, W. in <i>Gut Peptides: Biochemistry and Physiology</i> , Chapter 20, "Epidermal Growth Factor and Transforming Growth Factor-alpha" eds. Walsh and Dockray, Raven Press Ltd. New York, 1994.					

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.